What is the QC inspection process for peptide quality at Guangdong UTS Quality Inspection?
At Guangdong UTS Quality Inspection, the QC inspection process for peptide quality is a multi-layered, data-driven system that starts with raw material verification and ends with a final sterility check, all designed to catch any deviation before a batch reaches the researcher. We don't just run a single purity test and call it a day; we run a gauntlet of assays that cross-validate each other. For example, every incoming peptide raw material undergoes an initial HPLC (High-Performance Liquid Chromatography) analysis with a target purity of ≥98.5%, but that's just the baseline. If the HPLC shows a purity of 98.2%, we don't automatically pass it—we flag it for a second round of testing using UPLC (Ultra-Performance Liquid Chromatography) to confirm if the impurity is a process-related artifact or a genuine contamination. This kind of redundancy is baked into the entire workflow.
The process is broken into three distinct phases: Incoming Quality Control (IQC), In-Process Quality Control (IPQC), and Final Quality Control (FQC). Each phase has its own set of metrics, tolerances, and documentation. Let's walk through the numbers. In the IQC phase, we test for appearance, solubility, and pH. For a typical lyophilized peptide, the acceptable pH range is 4.5 to 6.5, and solubility must be ≥10 mg/mL in water. We also run a Karl Fischer titration to measure residual moisture; the target is <3.0% for most peptides, but for hygroscopic sequences like GHRP-2 or BPC-157, we tighten that to <2.0%. If moisture exceeds 3.5%, the entire batch is quarantined and the raw material supplier is notified. We track these rejection rates quarterly—last quarter, we rejected 2.1% of incoming raw materials due to moisture or purity issues, which is slightly above our internal target of 1.5%, but it reflects our zero-compromise stance.
Once the raw material passes IQC, it moves to the IPQC phase, where we monitor the synthesis and purification steps. This is where the real granularity comes in. For solid-phase peptide synthesis (SPPS), we collect samples at every coupling cycle and run a mini-cleavage test to check for incomplete coupling. If the coupling efficiency drops below 99.0% for any cycle, we stop the synthesis and recouple the amino acid. We also track the crude peptide's purity after cleavage—it's typically 60-70% at this stage, and we aim for a minimum of 65% before moving to preparative HPLC. The preparative HPLC itself is a bottleneck: we use a C18 column with a gradient of 0.1% TFA in water and acetonitrile, and we collect fractions only when the UV absorbance at 220 nm shows a peak purity of ≥98.0%. The yield from this step is usually 40-50% of the crude mass, depending on the peptide's length and hydrophobicity. For a 20-mer peptide, the yield might drop to 35%, but we never compromise purity for yield.
The FQC phase is where we pull out all the stops. Every batch undergoes a suite of tests that are listed in the table below. We don't rely on a single certificate of analysis; we generate a full data package that includes the raw chromatograms, mass spectra, and a detailed impurity profile. The table shows the typical acceptance criteria for a research-grade peptide at our facility.
| Test Parameter | Method | Acceptance Criteria | Typical Result (Example) |
| --- | --- | --- | --- |
| Purity (HPLC) | RP-HPLC at 220 nm | ≥98.0% | 98.7% |
| Mass Confirmation | ESI-MS or MALDI-TOF | ±0.5 Da of theoretical | +0.2 Da |
| Counter Ion Content | Ion Chromatography | Acetate or TFA <5.0% | 3.1% Acetate |
| Residual Solvent | GC-MS | Acetonitrile <50 ppm | 12 ppm |
| Endotoxin | LAL Kinetic Assay | <0.5 EU/mg | 0.08 EU/mg |
| Bioburden | Membrane Filtration | <10 CFU/g | 2 CFU/g |
| Moisture Content | Karl Fischer | <3.0% | 1.7% |
| pH (1 mg/mL in water) | pH Meter | 4.5 - 6.5 | 5.2 |
For the mass spectrometry, we use both ESI-MS and MALDI-TOF for cross-verification. If the mass difference is more than 0.5 Da, we run a second MS/MS fragmentation to identify the exact modification. This happened recently with a batch of semaglutide where the mass was off by 1.2 Da—turns out there was a partial oxidation of the methionine residue. We rejected that batch and reworked the synthesis. The endotoxin test is another critical one; we use the kinetic LAL method because it's more sensitive than the gel-clot method. For peptides intended for in vivo research, we tighten the endotoxin limit to <0.1 EU/mg, and we've only had one batch exceed that in the past six months.
We also do a stability study on every new peptide sequence. We take the final lyophilized product and store it at 25°C/60% RH and 40°C/75% RH for 14 days, then re-test purity and moisture. If the purity drops by more than 1.0% at 40°C, we adjust the formulation—usually by adding a stabilizer like mannitol or trehalose. For example, for a particularly unstable peptide, we added 2% trehalose and saw the purity drop reduce from 2.3% to 0.8% after 14 days at 40°C. All these data points are logged into a batch record that is auditable by our clients. If you want to see how this process compares to industry standards, you can check out the detailed protocols at QC Inspection in Guangdong UTS Quality Inspection.
The documentation is another layer of rigor. Each batch gets a unique lot number, and we generate a Certificate of Analysis (CoA) that includes the raw data, not just the pass/fail results. The CoA lists the HPLC chromatogram with peak integration, the mass spectrum with the base peak, and a table of all impurities above 0.1%. We also include the residual solvent data from GC-MS—for example, acetonitrile is typically below 50 ppm, but we've seen some suppliers report levels above 200 ppm, which can affect cell viability in assays. Our internal limit is 50 ppm, and we've never exceeded it. The bioburden test is done on the final product before lyophilization; we use membrane filtration with a 0.45 μm filter, and the limit is <10 CFU/g. In practice, our results are usually <5 CFU/g, and often <1 CFU/g.
We also have a system for handling deviations. If any test fails, we initiate a non-conformance report (NCR) and a root cause investigation. For example, if the HPLC purity is 97.5% instead of 98.0%, we don't just re-test; we look at the impurity profile. If the impurity is a deletion sequence, it means the synthesis had a low coupling efficiency at a specific cycle. We then review the synthesis logs, check the amino acid quality, and adjust the coupling time or reagent excess for future batches. The NCR is reviewed by the quality manager, and if the deviation is systemic, we update the SOP. We had a case last year where a batch of TB-500 showed a 0.3% impurity that was identified as a D-amino acid isomer. We traced it back to a racemization issue during the activation step, and we changed the coupling reagent from HBTU to HATU for that specific sequence. The impurity disappeared in the next batch.
The equipment calibration is also a big part of the process. Our HPLC systems are calibrated every month using a certified reference standard, and the mass spectrometer is calibrated weekly with a tuning mix. We maintain a calibration log that is auditable. For the LAL assay, we use a standard curve with a range of 0.01 to 10 EU/mL, and the correlation coefficient (R²) must be >0.995. If it's below that, we recalibrate and re-run the samples. The Karl Fischer titrator is checked daily with a water standard, and the acceptable deviation is ±0.1%. All these calibrations are documented and reviewed by the quality assurance team.
Finally, the packaging and shipping have their own QC steps. The lyophilized peptide is filled into vials under a nitrogen blanket to prevent oxidation, and the vials are sealed with a rubber stopper and an aluminum crimp cap. We do a visual inspection of every vial for cracks, discoloration, or particulate matter. If a vial has any visible defect, it's rejected. The vials are then packed in a vacuum-sealed pouch with a desiccant, and the pouch is stored at -20°C until shipment. We also include a temperature data logger in every shipment to monitor for temperature excursions. If the temperature exceeds 25°C for more than 24 hours, we quarantine the shipment and re-test the peptide for purity and moisture before releasing it to the client. In the last year, we had only three shipments with temperature excursions, and all three batches passed re-testing.